Novo Nordisk's (NVO) controlling shareholder, Novo Holdings, is looking to double the size of Catalent over five years as President-elect Donald Trump is likely to focus on US manufacturing, Reuters reported, citing an interview with a Novo Holdings senior partner.
Jonathan Levy said the company did not want to set a revenue target before agreeing on a corporate strategy with Catalent's management but noted that "doubling the size of your business over five years is always a nice barometer to work on," according to the report.
Levy said Catalent is set to hold its next board meeting in February, Reuters added.
Novo Holdings and Catalent did not immediately respond to MT Newswires' requests for comments.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。